加载中
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins. This compound is currently undergoing Phase 1/2 clinical trials for the treatment of multiple myeloma and various non-Hodgkin lymphomas, such as peripheral T-cell lymphoma and mantle cell lymphoma. Additionally, C4 Therapeutics is advancing several other programs: CFT8634, an orally bioavailable BiDAC degrader targeting the BRD9 protein, for potential use in synovial sarcoma and SMARCB1-deleted solid tumors. CFT1946, an orally administered BiDAC degrader designed to act on the V600X mutant BRAF, aimed at indications like melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies. CFT8919, an orally available, allosteric, and mutant-selective BiDAC degrader specifically targeting epidermal growth factor receptor (EGFR) with an L858R mutation in NSCLC. Their early-stage pipeline also features RET degraders for various forms of cancer. C4 Therapeutics, Inc. has formed strategic partnerships with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Biogen MA, Inc., and Calico Life Sciences LLC. The company was established in 2015 and its headquarters are located in Watertown, Massachusetts.
前收盘价
US$3.16
+US$0.31 · +10.88%
盘中时间采用ET。市场数据可能有所延迟。
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins. This compound is currently undergoing Phase 1/2 clinical trials for the treatment of multiple myeloma and various non-Hodgkin lymphomas, such as peripheral T-cell lymphoma and mantle cell lymphoma. Additionally, C4 Therapeutics is advancing several other programs: CFT8634, an orally bioavailable BiDAC degrader targeting the BRD9 protein, for potential use in synovial sarcoma and SMARCB1-deleted solid tumors. CFT1946, an orally administered BiDAC degrader designed to act on the V600X mutant BRAF, aimed at indications like melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies. CFT8919, an orally available, allosteric, and mutant-selective BiDAC degrader specifically targeting epidermal growth factor receptor (EGFR) with an L858R mutation in NSCLC. Their early-stage pipeline also features RET degraders for various forms of cancer. C4 Therapeutics, Inc. has formed strategic partnerships with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Biogen MA, Inc., and Calico Life Sciences LLC. The company was established in 2015 and its headquarters are located in Watertown, Massachusetts.
日内区间
当前US$3.16
52周区间
当前US$3.16
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
57
合理估值
情绪
53
多空交织
风险
68
高风险
动量
67
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins. This compound is currently undergoing Phase 1/2 clinical trials for the treatment of multiple myeloma and various non-Hodgkin lymphomas, such as peripheral T-cell lymphoma and mantle cell lymphoma. Additionally, C4 Therapeutics is advancing several other programs: CFT8634, an orally bioavailable BiDAC degrader targeting the BRD9 protein, for potential use in synovial sarcoma and SMARCB1-deleted solid tumors. CFT1946, an orally administered BiDAC degrader designed to act on the V600X mutant BRAF, aimed at indications like melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies. CFT8919, an orally available, allosteric, and mutant-selective BiDAC degrader specifically targeting epidermal growth factor receptor (EGFR) with an L858R mutation in NSCLC. Their early-stage pipeline also features RET degraders for various forms of cancer. C4 Therapeutics, Inc. has formed strategic partnerships with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Biogen MA, Inc., and Calico Life Sciences LLC. The company was established in 2015 and its headquarters are located in Watertown, Massachusetts.
日内区间
当前US$3.16
52周区间
当前US$3.16
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 3594.7万 USD | 3558.4万 USD | 2075.6万 USD | 3109.6万 USD | 4578.5万 USD |
| 销货成本 | 797.5万 USD | — | 773.7万 USD | — | — |
| 毛利 | 2797.2万 USD | 3558.4万 USD | 1301.9万 USD | 3109.6万 USD | 4578.5万 USD |
| 研究与开发 | 1.04亿 USD | 1.11亿 USD | 1.18亿 USD | 1.18亿 USD | 9466.5万 USD |
| 销售、一般及管理费用 | 3619.6万 USD | 4212.4万 USD | 4208.1万 USD | 4278.9万 USD | 3325.4万 USD |
| 营业费用 | 1.32亿 USD | 1.55亿 USD | 1.52亿 USD | 1.61亿 USD | 1.28亿 USD |
| 利息收入 | 1034.9万 USD | 1442.9万 USD | 981.2万 USD | 357.5万 USD | 38.7万 USD |
| 利息支出 | — | — | 137.3万 USD | 221.6万 USD | 214.5万 USD |
| 折旧和摊销 | 195.9万 USD | 181.8万 USD | 188万 USD | 167.6万 USD | 149.2万 USD |
| 营业利润 | −1.04亿 USD | −1.2亿 USD | −1.39亿 USD | −1.3亿 USD | −8213.4万 USD |
| 净利润 | −1.05亿 USD | −1.05亿 USD | −1.32亿 USD | −1.28亿 USD | −8389.2万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1211.29万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM775.65万0.01%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF394.03万0.00%954亿 USD0.05%US$235+0.80%
Fidelity Enhanced Small Cap ETFFESM302.71万0.05%64.1亿 USD0.28%US$45.46+0.46%
iShares Biotechnology ETFIBB248.05万0.02%108.2亿 USD0.44%US$206.49+3.00%
Vanguard Russell 2000 ETFVTWO216.52万0.01%180亿 USD0.06%US$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA157.79万0.01%218.24亿 USD0.03%US$32.79+0.40%
Dimensional - US Small Cap ETFDFAS128.73万0.00%338.69亿 USD0.31%US$78.35+0.32%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHADimensional - US Small Cap ETFDFASAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
